The addition of local ablative therapy for primary and metastatic sites to PD‐1/PD‐L1 inhibitors plus chemotherapy may improve survival outcomes by reducing the tumour burden, which should be further evaluated in prospective trials. Here, PDCD1 is linked to neoplasm.